Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 22Bevacizumab 20Carboplatin 19liposomal doxorubicin 14Specimen Handling 14Magnetic Resonance Spectroscopy 13olaparib 12Topotecan 9Gemcitabine 9Biopsy 8pembrolizumab 7Taxes 6Immunoglobulin G 6Disulfides 6niraparib 4mirvetuximab soravtansine 4cediranib 4Doxorubicin 4oregovomab 3Nivolumab 3Cyclophosphamide 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Oxaliplatin 2Docetaxel 2Cisplatin 2Biosimilar Pharmaceuticals 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × rucaparib × 90 days × Clear all
NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
72 enrolled 16 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04539327 2026-03-18

Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

Grupo Español de Investigación en Cáncer de Ovario

Completed
51 enrolled 28 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡